CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 264 enrolled
Drug / intervention
AliveCor +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02731326
NCT02731326N/ACompleted

iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology

Columbia University·interventional·Posted Apr 7, 2016·Updated Jul 3, 2024

In Brief

A clinical study evaluating AliveCor and Behavioral Altering Messaging for Atrial Fibrillation and Atrial Flutter. Completed, enrolled 264 participants across 1 site.

Detailed Summary

Atrial fibrillation (AF), a condition where the top chambers of the heart beat irregularly, is a major health problem. The long-term goal of this project is to use a personal, mobile heart monitor to help patients better recognize recurrent AF and improve patients' ability to better manage their condition. A total of 300 patients with a history of AF will be included in the study, with 150 patients receiving an iPhone with the mobile monitoring device and educational text messaging and the remaining 150 patients continuing with their regular medical care. Each patient will be included in the intervention period for 6 months. The rate of recurrent AF and treatments meant to manage AF and other heart conditions will be determined for both groups. Patients in both groups will complete a series of questionnaires at the start and end of the 6 month study period to look at differences in quality of life and knowledge of AF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 7, 2016
Enrollment StartMar 1, 2015
Primary CompletionAug 31, 2019
Study CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 10.2 years ago

Interventions

AliveCordevice

The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, "AliveECG". It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor "cloud".

Behavioral Altering Messagingbehavioral

Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number